top of page


Cancer52 analysis on rare and less common cancer research spend
Cancer52 and the National Cancer Research Institute (NCRI) joined forces to create a report titled: Research into rare and less common...
A joint statement on the voluntary scheme for branded medicines pricing and access (VPAS)
Patient charities set out a shared vision for the next VPAS scheme. Cancer52 have joined forces with the Charity Medicines Access...


Cancer52 Annual Review 2021-2022
We are incredibly pleased to present our Annual Review for the financial year 2021-2022. It covers the period following the COVID-19...


Cancer52 launches inequalities report
Cancer52 are pleased to launch our report - Taking Action on Inequalities in Rare and Less Common Cancers: Understanding the Issues – at...
Showcase Video
From the start of the COVID-19 pandemic, we saw the incredible commitment of members in pulling out all the stops to meet the needs of...


Annual Review 2020-21
Cancer52 is delighted to present its Annual Review 2020-21. This report particularly highlights the strength and impact of Cancer52’s...
The impact of the Covid-19 pandemic on people with rare and less common cancers - Report published
Working with Keep up with Cancer[i] Cancer52 has published a new report which covers the impact of Covid-19 on people with rare and less...
Cancer52 publishes England results of its second patient survey
With help from its member charities, Cancer52 ran a second survey of people with rare and less common cancers from early December 2020 to...
Health and Social Care Select Committee Report
The Health and Social Care Select Committee have published their report on the inquiry 'Delivering core NHS and care services during the...
Cancer52 publishes England results of its patient survey
During June 2020 Cancer52 with help from many of its member charities ran a survey of people with rare and less common cancers to...
bottom of page
